Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the clinical effects of multiple (28 day)
twice-daily doses of OC000459 in comparison to placebo on clinic lung function (FEV1) in mild
to moderate asthmatics with an FEV1 of 60-80% of predicted and requiring only short acting
inhaled B2-adrenergic agonists for symptomatic control.